Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Well, this wraps up one of the most eventful weeks of the biotech year — ASCO, followed by BIO. Anyone else as zonked as I am? Today, we discuss the impact that the BIOSECURE Act is already having on the industry, preview what FDA reviewers want to know about donanemab, and more.

advertisement

The need-to-know this morning

  • The FDA approved Geron‘s drug imetelstat for certain patients with myelodysplastic syndromes, a type of slow-moving blood cancer.  Marketed as Rytelo, it’s the first drug to emerge from the once-ballyhooed company since its founding in 1990.

BIOSECURE shaking up partnerships at BIO

Although it isn’t yet a law, the BIOSECURE Act is already making waves in the biotech industry — as evidenced by some notable shifts at this week’s BIO International Convention in San Diego. STAT’s Jonathan Wosen and I were on site, and found that, with the possible blacklisting of certain Chinese suppliers looming, biotechs are scrambling to find alternatives to manufacturers like WuXi. Meantime, an executive at one U.S.-based CDMO said “month to month, new business has gone through the roof.”

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.